A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis

Trial Profile

A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs Lyophilised Oxalobacter formigenes (Primary)
  • Indications Primary hyperoxaluria
  • Focus Therapeutic Use
  • Sponsors OxThera
  • Most Recent Events

    • 20 Feb 2018 Planned number of patients changed from 9 to 12.
    • 13 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Feb 2020.
    • 13 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top